Developed by state-owned Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik V coronavirus vaccine was the first to pass trials and it has one of the best safety and efficacy records among the group of 5 or 6 available to the global community.
According to Telesur:
Russia has already signed contracts with 15 companies from ten nations to produce around 1.4 billion doses, which would immunize 700 million people.
